Compare Moderna, Inc. (MRNA) vs Ulta Beauty Inc (ULTA) Price & Performance

Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.

Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.

ULTA Beauty trades at $570.02, up 4.5% today, showing strong momentum with a bullish technical setup and positive analyst sentiment. The company delivered Q2 2026 earnings beat ($6.55 actual vs. $6.22 expected) and raised 2026 guidance, supported by robust e-commerce growth. Valuation metrics show a P/E of 20.55 and P/S of 1.92, while profitability remains solid with 39.3% gross margins and 46.1% ROE. Recent news highlights expansion into wellness categories and omnichannel strength.

Outlook remains positive with consensus price target of $624.93 (9.6% upside), though margin pressure and flat store traffic pose execution risks. The stock's current price near resistance at $572 suggests potential near-term consolidation before further gains. Institutional ownership trends show mixed activity with recent CEO share sales offset by pension fund accumulation.